Status and phase
Conditions
Treatments
About
The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection.
Full description
The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection. Actually, if the 14v lymph node metastasis is suspected before surgery, it is excluded from the study. In a retrospective study conducted in our hospital, we compared the patients with the 14v lymphadenectomy group and those without the 14v lymphadenectomy group, the survival rate of the 14v lymphadenectomy group was 11% higher than that of the 14v non-lymphadenectomy group.Previous studies have suggested that the presence of metastatic lymph nodes in the 14v lymph node is not good and that removal of the 14v lymph node does not affect prognosis. However, if the lymph node is a continuous tissue and the transition to the 14v lymph node is confirmed microscopically, a negative prognosis may be expected because it is likely that the cancer has spread to the distal lymph node. In addition, inadequate resection of the lymphatic or 14v lymph node adjacent to the 14v lymph node in the absence of evidence of metastasis of the 14v lymph node under microscopic examination indicates that cancer may spread even after curative surgery, To prevent cancer metastasis.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
<Inclusion Criteria>
Histologically proven primary gastric adenocarcinoma
T3N+, T4N+ by CT scan (AJCC 7th classification)
Distal margin of gastric cancer Location of distal margin of gastric cancer ; antrum, or angle of the stomach
No evidence of other distant metastasis
Age ≥ 20 year old
Performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
No prior treatment of chemotherapy or radiation therapy against any other malignancies, and no prior treatment for gastric cancer including endoscopic mucosal resection
Adequate organ functions defined as indicated below:
Written signed informed consent
<Exclusion Criteria>
Primary purpose
Allocation
Interventional model
Masking
518 participants in 2 patient groups
Loading...
Central trial contact
HONG MAN YOON, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal